<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480465</url>
  </required_header>
  <id_info>
    <org_study_id>39DM14010</org_study_id>
    <nct_id>NCT02480465</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lobeglitazone Versus Sitagliptin</brief_title>
  <official_title>Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by
      Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by
      Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome: 24-week,
      Multi-center, Randomized, Double-blind, Phase 4 Study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean percent change of HbA1c</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of Metabolic Syndrome</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Metabolic Syndrome Components(HDL-C, TG, BP, waist line)</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Glycemic parameters(FPG, HOMA-IR, HOMA- β, QUICKI)</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Lipid parameters(Total Cholesterol, LDL-C, HDL-C, Small Dense LDL-C, FFA, Apo-B)</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The achivement rate of HbA1c(HbA1c &lt; 6.5%, HbA1c &lt; 7%)</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Adiponectin</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of hs-CRP</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation - physical examination, vital sign, laboratory, adverse event</measure>
    <time_frame>from baseline at 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lobelitazone 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobelitazone 0.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobelitazone 0.5mg</intervention_name>
    <description>Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin</description>
    <arm_group_label>Lobelitazone 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <description>placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin</description>
    <arm_group_label>Sitagliptin 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥19 years old

          -  Waist line: male ≥ 90cm, female ≥ 85cm

          -  Applied to 1 or more categories listed below (NCEP-ATP III)

               1. SBP ≥ 130mmHg and/or DBP ≥ 85mmHg and/or taking drug for BP control

               2. HDL-C: male &lt; 40mg/dl, female &lt; 50mg/dl and/or taking drug for HDL-C increase

               3. TG ≥ 150mg/dl and/or taking drug for TG control

          -  At visit 1: Applied to 1 or more categories listed below

               1. Type 2 DM Patients who does not need stabilization period : 7% ≤ HbA1c ≤ 10%, if
                  treated with Metformin ≥ 1000mg monotherapy at least 12 weeks prior to this study
                  → Visit 3(Randomization)

               2. Type 2 DM Patients who need stabilization period : 7% ≤ HbA1c ≤ 10%, if not
                  treated with Metformin ≥ 1000mg monotherapy at least 12 weeks prior to this study
                  (Applied to 1 or more categories listed below) ① Drug Naïve ② Taking Metformin &lt;
                  1000mg monotherapy and/or Taking Metformin &lt; 12 weeks prior to this study ③
                  Taking OHA

          -  At visit 2(After 12 weeks of stabilization period): 7% ≤ HbA1c ≤ 10%

          -  Patients who signed informed consent form

        Exclusion Criteria:

          -  Type 1 DM Patients or secondary DM

          -  Patients with ketoacidosis

          -  Patients with taking insulin &gt; 7 days within 12 weeks

          -  Hypersensitive to biguanide and/or glitazone and/or DPP4-inhibitor

          -  Patients with taking corticosteroid &gt; 7 days within 4 weeks

          -  Patients with lactic acidosis

          -  Patients with galactose intolerance and/or Lapp lactase deficiency and/or
             glucose-galactose malabsorption

          -  Patients with innutrition and/or starvation and/or weakness and/or pituitary
             insufficiency and/or addisons disease

          -  History of malignant tumor within 5 years

          -  History of drug or alcohol abuse within 12 weeks

          -  Patients with congestive heart failure(NYHA class III~IV) or uncontrolled arrythmia
             within 6 months

          -  Patients with acute cardiovasvular disaese with 12 weeks

          -  Applied to 1 or more categories listed below

               1. AST and/or ALT ≥ 3*ULN

               2. Serum creatinine: male ≥ 1.5mg/dl, female ≥ 1.4mg/dl

               3. Hb &lt; 10.5g/dl

          -  Women with pregnant, breast-feeding

          -  Childbearing age who don't use adequate contraception

          -  Patients who have participated in other clinical trials

          -  Not eligible to participate for the study at the discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Sub Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Kyung Oh</last_name>
    <phone>82-2-2194-0469</phone>
    <email>hkoh@ckdpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-sub Choi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

